Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 02: 130 - 132

DOI: https://doi.org/10.16150/j.1671-2870.2022.02.004

Expert advice

Expert suggestion for pituitary disease management during the recent COVID-19 pandemic

Expand
  • National Metabolic Diseases Clinical Research Center (Shanghai)

Received date: 2022-05-26

  Online published: 2022-04-25

Fold

Abstract

Pituitary disease are often associated with hormonal abnormalities, mass effects and multiple co-morbidities, involving multidisciplinary management and follow-up. The COVID-19 pandemic makes their management much more challenging. Therefore, this expert suggestion aims to standardize the diagnosis and treatment of pituitary disease and strengthen the management of co-morbidities during the current COVID-19 epidemic.

Key words： COVID-19; Pituitary disease; Co-morbidities

Cite this article

Chinese Society of Endocrinology,Chinese Medical Association , et al . Expert suggestion for pituitary disease management during the recent COVID-19 pandemic[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(02) : 130 -132 . DOI: 10.16150/j.1671-2870.2022.02.004

References

[1] Yuen KCJ, Blevins LS Jr, Findling JW. Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic[J]. Endocr Pract, 2020, 26(8):915-922.
[2] Fleseriu M, Dekkers OM, Karavitaki N. Endocrinology in the time of COVID-19: Management of pituitary tumours[J]. Eur J Endocrinol, 2020, 183(1):G17-G23.
[3] Fleseriu M, Buchfelder M, Cetas JS, et al. Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective[J]. Pituitary, 2020, 23(4):327-337.
[4] Christ-Crain M, Hoorn EJ, Sherlock M, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2020, 183(1):G9-G15.
[5] 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):751-760.
[5] Endocrinology branch of Chinese Medical Association. Chinese expert consensus on acromegaly diagnosis and treatment(2020 Edition)[J]. Chin J Endocrinol Metab, 2020, 36(9):751-760.
[6] 中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27):2115-2126.
[6] Chinese pituitary adenoma cooperation group. Consensus on diagnosis and treatment of acromegaly in China (2021 Edition)[J]. Natl Med J China, 2021, 101(27):2115-2126.
[7] 中国垂体腺瘤协作组. 中国库欣病诊治专家共识(2015)[J]. 中华医学杂志, 2016, 96(11):835-840.
[7] Chinese pituitary adenoma cooperation group. Consensus of Chinese experts on diagnosis and treatment of Cushing′s disease(2015)[J]. Natl Med J China, 2016, 96(11):835-840.
[8] Pivonello R, Ferrigno R, Isidori AM, et al. COVID-19 and Cushing′s syndrome: recommendations for a special population with endogenous glucocorticoid excess[J]. Lancet Diabetes Endocrinol, 2020, 8(8):654-656.
[9] Newell-Price J, Nieman LK, Reincke M, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing′s syndrome[J]. Eur J Endocrinol, 2020, 183(1):G1-G7.
[10] 王卫庆, 单忠艳, 王广, 等. 新型冠状病毒肺炎疫情期间糖尿病基层管理专家建议[J]. 中华内分泌代谢杂志, 2020, 36(3):185-190.
[10] Wang WQ, Shan ZY, Wang G, et al. Expert advice on diabetes management at the grass-roots level during the outbreak of novel coronavirus pneumonia[J]. Chin J Endocrinol Metab, 2020, 36(3):185-190.
[11] 中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1):1-10.
[11] Endocrinologist branch of Chinese Medical Association, Chinese inpatient blood glucose management expert group. Consensus of Chinese inpatient blood glucose management experts[J]. Chin J Endocrinol Metab, 2017, 33(1):1-10.
[12] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4):311-398.
[12] Diabetes branch of Chinese Medical Association. Guidelines for prevention and treatment of type 2 diabetes in China (2020 Edition)[J]. Chin J Endocrinol Metab, 2021, 37(4):311-398.
[13] 中华医学会内分泌学分会肥胖学组. 肾上腺皮质功能减退症患者围手术期糖皮质激素管理专家共识[J]. 中华内分泌代谢杂志, 2022, 38(1):1-6.
[13] Obesity group, endocrinology branch, Chinese Medical Association. Expert consensus on perioperative glucocorticoid management in patients with adrenocortical insufficiency[J]. Chin J Endocrinol Metab, 2022, 38(1):1-6.
Options
Outlines

/

〈 〉